Relevant bibliographies by topics / Silodosin

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters

Academic literature on the topic 'Silodosin'

Author: Grafiati
Published: 9 March 2023
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Silodosin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Silodosin"

1

Ahmed, Masud, Prodyut Kumar Saha, Kartik Chandra Ghosh, SK Amirul Islam, and Nirupom Mondal. "Comparative study between Silodosin alone and Silodosin plus Tadalafil for the medical management of lower Ureteric Stone in South-Western part of the Bangladesh." Bangladesh Journal of Urology 23, no. 1 (November 15, 2020): 67–71. http://dx.doi.org/10.3329/bju.v23i1.50293.

Full text
Abstract:
Objective: To compare the treatment outcome of Silodosin alone and Silodosin plusTadalafil as a medical expulsive therapy (MET) of lower ureteric stone in south-westernpart of Bangladesh. Methodology: The study was conducted in a tertiary hospital in Khulna, over a periodof 12 months (January 2019 to December 2019). Out of 108 patients, 100 meet theinclusion criteria who were purposively assigned into 2 groups. 48 patients included inSilodosin alone group and 52 in Silodosin plus Tadalafil group. Result: There was a significant higher stone expulsion rate in Silodosin plus Tadalafilthan Silodosin alone which was 88.46% vs75% respectively (P value 0.02). The meanstone expulsion time of Silodosin alone was14.33 (±3.1) days and Silodosin plus Tadalafilwas 11.48(±2.3) days (P value 0.001). The episodes of pain in Silodosin alone were0.7(±0.06) and 0.6(±0.2) in Silodosin plus Tadalafil group that was statisticallysignificant. Conclusion: The present study concludes that Silodosin plus tadalafil combinationtherapy significantly increases ureteric stone expulsion rate and decreases the expulsiontime and pain episodes than treatment with silodosin alone. Bangladesh Journal of Urology, Vol. 23, No. 1, January 2020 p.67-71
APA, Harvard, Vancouver, ISO, and other styles
2

Curran, Monique P. "Silodosin." Drugs 71, no. 7 (May 2011): 897–907. http://dx.doi.org/10.2165/11204780-000000000-00000.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tanaka, Yoshinori, Yasushi Tanuma, and Naoya Masumori. "The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia." Advances in Urology 2017 (2017): 1–6. http://dx.doi.org/10.1155/2017/4842025.

Full text
Abstract:
Objectives. The persistence of silodosin and the reasons for withdrawal from treatment of previously untreated Japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) were evaluated in real-life clinical practice.Methods. A total of 81 previously untreated Japanese patients diagnosed with LUTS/BPH were treated with silodosin monotherapy and prospectively followed for 4 years. The persistence rate was estimated using the Kaplan-Meier method. If silodosin had to be terminated or a patient did not come to the hospital, the reason was determined.Results. The 6-month, 1-year, 2-year, 3-year, and 4-year persistence rates were 63.0%, 56.8%, 50.6%, 44.4%, and 35.8%, respectively. The most frequent reason (22.2%) for withdrawal was symptom resolution. After silodosin treatment, the international prostate symptom score and the quality of life index were significantly improved and maintained for 4 years.Conclusions. 35.8% of previously untreated Japanese patients continued silodosin for 4 years. Many patients terminated silodosin for various reasons, the most frequent of which was symptom resolution. The effects of silodosin were maintained when the patients continued treatment.Trial Registration. This study was approved by the institutional review board of Hokkaido Prefectural Esashi Hospital (number 2007-2) and was registered in a public trial registry (UMIN000026910).
APA, Harvard, Vancouver, ISO, and other styles
4

Jung, Hae Do, Kang Su Cho, Dae Young Jun, Jae Yong Jeong, Young Joon Moon, Doo Yong Chung, Dong Hyuk Kang, Seok Cho, and Joo Yong Lee. "Silodosin versus Tamsulosin for Medical Expulsive Therapy of Ureteral Stones: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials." Medicina 58, no. 12 (December 6, 2022): 1794. http://dx.doi.org/10.3390/medicina58121794.

Full text
Abstract:
Background and Objectives: This systematic review and meta-analysis of randomized controlled trials was performed to compare the therapeutic effects and safety profiles of silodosin and tamsulosin for medical expulsive therapy (MET) of ureteral stones. Materials and Methods: We searched PubMed, EMBASE, the Cochrane Library, and Web of Science to identify articles published before July 2022 that described randomized controlled trials comparing silodosin and tamsulosin for MET of ureteral stones. Endpoints were stone expulsion rate, stone expulsion time, and total complication rate. Results: In total, 14 studies were included in our analysis. The size of ureteral stones was <1 cm. Compared with tamsulosin, silodosin resulted in a significantly higher stone expulsion rate (p < 0.01, odds ratio (OR) = 2.42, 95% confidence interval (CI) = 1.91 to 3.06, I2 = 0%) and significantly shorter stone expulsion time (p < 0.01, mean difference = −3.04, 95% CI = −4.46 to −1.63, I2 = 89%). The total complication rate did not significantly differ between silodosin and tamsulosin (p = 0.33, OR = 1.15, 95% CI = 0.87 to 1.52, I2 = 7%). Conclusions: Compared with tamsulosin, silodosin resulted in significantly better expulsion of ureteral stones <1 cm. The total complication rate did not significantly differ between silodosin and tamsulosin. Thus, silodosin may be superior to tamsulosin for MET of ureter stones <1 cm.
APA, Harvard, Vancouver, ISO, and other styles
5

Imperatore, Vittorio, Ferdinando Fusco, Massimiliano Creta, Sergio Di Meo, Roberto Buonopane, Nicola Longo, Ciro Imbimbo, and Vincenzo Mirone. "Medical expulsive therapy for distal ureteric stones: tamsulosin versus silodosin." Archivio Italiano di Urologia e Andrologia 86, no. 2 (June 30, 2014): 103. http://dx.doi.org/10.4081/aiua.2014.2.103.

Full text
Abstract:
Objectives: To compare the efficacy and safety of tamsulosin and silodosin in the context of medical expulsive therapy (MET) of distal ureteric stones. Patients and methods: Observational data were collected retrospectively from patients who received silodosin (N = 50) or tamsulosin (N = 50) as MET from January 2012 to January 2013. Inclusion criteria were: patients aged ≥ 18 years with a single, unilateral, symptomatic, radiopaque ureteric stone of 10 mm or smaller in the largest dimension located between the lower border of the sacroiliac joint and the vesico-ureteric junction. Stone expulsion rate, stone expulsion time, number of pain episodes, need for analgesics use, incidence of side effects were compared. Results: Stone-expulsion rate in the silodosin and in the tamsulosin groups were 88% and 82%, respectively (p not significant). Mean expulsion times were 6.7 and 6.5 days in the silodosin and tamsulosin group, respectively (p not significant). Mean number of pain episodes were 1.6 and 1.7 in the silodosin and tamsulosin group, respectively (p not significant). The mean number of analgesic requirement was 0.84 and 0.9 for the silodosin and tamsulosin group, respectively (p not significant). Overall, incidence of side effects was similar in both groups. Patients taking silodosin experienced an higher incidence of retrograde ejaculation but a lower incidence of side effects related to peripheral vasodilation when compared to patients taking tamsulosin. Subgroup analysis demonstrated significantly lower mean expulsion times and pain episodes in patients with stones ≤ 5 mm in both groups. Conclusions: Tamsulosin and silodosin are equally effective as MET for distal ureteric stones sized 10 mm or smaller. MET with silodosin is associatd with a lower incidence of side effects related to peripheral vasodilation but an higher incidence of retrograde ejaculation when compared to tamsulosin.
APA, Harvard, Vancouver, ISO, and other styles
6

Cakiroglu, Basri, Aydin Ismet Hazar, Orhun Sinanoglu, Ersan Arda, and Sinan Ekici. "Comparison of transurethral incision of the prostate and silodosin in patients having benign prostatic obstruction in terms of retrograde ejaculation." Archivio Italiano di Urologia e Andrologia 89, no. 1 (March 31, 2017): 31. http://dx.doi.org/10.4081/aiua.2017.1.31.

Full text
Abstract:
Background: To compare the functional outcomes and retrograde ejaculation (RE) after transurethral incision of the prostate (TUIP) or silodosin in bladder outlet obstruction (BOO) secondary to a small prostate. Methods: Prospectively collected data from December 2011 through December 2014 of 192 LUTS patients having fertility concerns with prostate volume smaller than 40 ml receiving either TUIP or silodosin treatment were prospectively reviewed. The treatment outcomes were evaluated and compared. Results: TUIP was performed in 96 cases and silodosin 8 mg was prescribed in 96 cases. At 12<sup>th</sup> months after TUIP or continuous silodosin treatment, the decrease in mean International Prostate Symptom Score (IPSS) and postvoiding residual urine (PVR) and the improvement of mean maximal flow rate (Q<sub>max</sub>) were significant (p = 0.000). The improvement in IPPS and Qmax was significantly higher in TUIP group compared to silodosin group (p = 0.005, p = 0.000) with a lower rate of retrograde ejaculation (RE) in TUIP group. (11/96 vs 33/96) (p = 0.000) Conclusions: Both TUIP and silodosin ensures comparable improvement in PVR, IPSS and Q<sub>max</sub> with a lower rate of RE on the TUIP group in prostates weighing less than 40 grams suggesting that TUIP is a better choice in younger patiens seeking preservation of ejaculation with fertility concerns.
APA, Harvard, Vancouver, ISO, and other styles
7

Klimi, Eleni. "A Probable Case of Mucosal Fixed Drug Eruption Following Treatment with Silodosin." Sultan Qaboos University Medical Journal [SQUMJ] 18, no. 3 (December 19, 2018): 402. http://dx.doi.org/10.18295/squmj.2018.18.03.025.

Full text
Abstract:
A fixed drug eruption consists of erythematous patches that appear on the skin and/or mucous membranes following administration of a drug which, once healed, leaves residual hyperpigmentation. We report a 76-year-old male who presented to the Thriasio General Hospital, Athens, Greece, in 2016 with erythema, oedema and blistering of the lower lip and glans penis following the administration of silodosin for benign prostatic hyperplasia. The eruption regressed two weeks after silodosin was discontinued.Keywords: Drug Eruption; Mucous Membranes; Erythema; Blister; Silodosin; Case Report; Greece.
APA, Harvard, Vancouver, ISO, and other styles
8

Hagovska, Magdalena, and Jan Svihra. "Evaluation of Silodosin and Pelvic Floor Muscle Training in Men with Benign Prostatic Hyperplasia and Overactive Bladder (Silodosing) Study Protocol (Spirit Compliant)." International Journal of Environmental Research and Public Health 18, no. 21 (October 30, 2021): 11426. http://dx.doi.org/10.3390/ijerph182111426.

Full text
Abstract:
The aim of our study will be to evaluate the effect of combining pelvic floor muscle training (PFMT) with the urgency-suppression technique and silodosin in comparison with silodosin alone in men with Benign Prostatic Hyperplasia (BPH) and Overactive Bladder (OAB) after 12 weeks of treatment. The primary outcome will be a change in the number of voidings and intensity of urgencies over 24 h using a micturition diary, and the secondary outcomes will be a change in lower urinary tract symptoms, a change in incontinence quality of life, a change in patients’ global impression of improvement, and a lower incidence of adverse events. A randomized intervention parallel multicenter study will be conducted in collaboration with 45 urological clinics at the national level. Patients will be assigned at a 1:1 ratio to the experimental and control groups using simple randomization according to odd and even patient sequence numbers in each ambulatory clinic. The experimental group will receive oral silodosin at a daily dose of 8 mg once daily and pelvic floor muscle training (PFMT) 5 times a week for 20–30 min a day, for 12 weeks. The control group will receive oral treatment with silodosin at a daily dose of 8 mg once daily for 12 weeks. The study protocol presents the starting points and design of a randomized, interventional, parallel, multicenter study looking at the effect of a combination of silodosin and PFMT versus silodosin treatment in men with BPH and OAB.
APA, Harvard, Vancouver, ISO, and other styles
9

Oyama, Nobuyuki, Yoshitaka Aoki, Hideaki Ito, Yoshiji Miwa, Hironobu Akino, Yoshitaka Sato, Hiroki Shioura, Hirohiko Kimura, and Osamu Yokoyama. "Alpha 1-Adrenoceptor Blocker May Improve Not Only Voiding But Also Storage Lower Urinary Tract Symptoms Caused by 125I Brachytherapy for Prostate Cancer." ISRN Urology 2014 (March 30, 2014): 1–8. http://dx.doi.org/10.1155/2014/140654.

Full text
Abstract:
Purpose. To assess changes in lower urinary tract symptoms (LUTS) within 1 year after brachytherapy in patients receiving alpha 1-adrenoceptor antagonists. Methods. We retrospectively evaluated 116 patients who underwent 125I prostate brachytherapy in our institute. Seventy-one patients were treated with a combination of external beam radiation therapy and brachytherapy. Alpha 1-adrenoceptor antagonists were prescribed to all patients after brachytherapy. International Prostate Symptom Score (IPSS) forms and postvoid residual urine volume were recorded at all follow-up visits. Results. Forty-nine patients were given tamsulosin hydrochloride, 32 were given silodosin hydrochloride, and 35 were given naftopidil for up to 6 months after seed implantation. Patients given tamsulosin or naftopidil tended to show a higher peak IPSS and slower recovery to baseline values than those given silodosin. The patients given naftopidil showed an insufficient recovery in storage symptoms in naftopidil group in comparison with tamsulosin group at 3 months and with silodosin group at 6 and 9 months. Conclusions. In the management of LUT after brachytherapy, silodosin may provide a more favorable improvement. Silodosin and tamsulosin may have an advantage in improving not only voiding but also storage lower urinary tract symptoms after brachytherapy.
APA, Harvard, Vancouver, ISO, and other styles
10

YAMAZAKI, Yoshinobu. "Development of Silodosin." YAKUGAKU ZASSHI 126, Special (March 1, 2006): 207–8. http://dx.doi.org/10.1248/yakushi.kj00004483554.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Silodosin"

1

Calogero, F. "NEW SYNTHETIC PROCESSES FOR THE APIS INDUSTRIAL PRODUCTION: THE CASE OF SILODOSIN." Doctoral thesis, Università degli Studi di Milano, 2014. http://hdl.handle.net/2434/243613.

Full text
Abstract:
This thesis is focused on the development of new synthetic processes for the production of already known Active Pharmaceutical Ingredients (APIs). The research work was performed in the laboratories of Dipharma Francis srl, a company which operates in the generic drug market. The launch of the generic version of a drug in the market often leads to lowering of product prices for both the branded product and the generic ones. For this reason, the process adopted to produce an API has to be innovative, efficient, safe and, of course, cheaper than the existing ones, in order to be competitive in the market. During my Ph.D. I worked on the synthesis of some APIs, in particular here I report the feasibility and development studies of an alternative process to produce silodosin. Silodosin is an API used as a treatment for the symptoms of Benign Prostatic Hyperplasia (BPH). In order to establish the synthetic strategy and to outline our freedom to operate, an accurate survey of the whole patent literature about silodosin has been done. During the feasibility study several synthetic approaches have been tried in order to functionalise indoline at positions 5 and 7. A copper(I) catalysed C-arylation reaction and a regioselective electrophilic aromatic substitution revealed to be the best choices to introduce respectively substituents in position 5 and 7 of indoline. The synthesis continued with a diastereoselective reductive amination which after crystallisation yielded optically pure amine intermediate that is the key intermediate for the synthesis of silodosin and ended converting amine intermediate into Silodosin using already reported procedures. Our new process to prepare silodosin starting from commercially available and cheap indoline consists of 11 steps. The whole synthetic route has been performed in gram scale using only 4 purifications of key intermediates. Silodosin has been finally obtained in a 10% overall yield, with a purity greater than 99% measured by HPLC and an optical purity greater than 99% measured by HPLC on chiral stationary phase.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Silodosin"

1

Yoshida, Masaki, Imao Mikoshiba, Katsuyoshi Akiyama, and Junzo Kudoh. "Silodosin (Urief®, Rapaflo®, Thrupas®, Urorec®, Silodix™): A Selective α1A Adrenoceptor Antagonist for the Treatment of Benign Prostatic Hyperplasia." In Case Studies in Modern Drug Discovery and Development, 360–91. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118219683.ch14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bylund, D. B. "Silodosin☆." In Reference Module in Biomedical Sciences. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-12-801238-3.98851-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"Silodosin." In Hale’s Medications & Mothers’ Milk™ 2019. New York, NY: Springer Publishing Company, 2018. http://dx.doi.org/10.1891/9780826150356.0936.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Albert, A. S., Santosh R. Pillai, Anila Mary, and Rajeev Aravindakshan. "An Investigator Led Clinical Trial in Practice Showing the Efficacy of Tamsulosin and Silodosin as Medical Expulsive Therapy in the Management of Distal Ureteral Stones: A Case Study in Urology." In Perspective of Recent Advances in Medical Research Vol. 12, 126–33. B P International (a part of SCIENCEDOMAIN International), 2023. http://dx.doi.org/10.9734/bpi/pramr/v12/18245d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Silodosin' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography